The here observed elevated CD169/SIGLEC1 expression levels in COVID-19 patients are in line with a previous report by Bedin and colleagues [7], who first described elevated CD169/SIGLEC1 expression in a small cohort of patients with COVID-19, but no differences in CD169/SIGLEC1 expression levels were observed between mild and severe cases. Here, SIGLEC1 is linked to COVID-19.